Associations of gamma-glutamyl transferase with cardio-metabolic diseases in people living with HIV infection in South Africa
South Africa, 2015
Kim A. Nguyen, Nasheeta Peer, Andre P. Kengne
Created on
January 18, 2021
Last modified
January 18, 2021
Page views
13625
Documentation in PDF
Metadata
DDI/XML
JSON
Identification
Survey ID Number
GGTandcardio-metabolicdiseases
Title
Associations of gamma-glutamyl transferase with cardio-metabolic diseases in people living with HIV infection in South Africa
Country
| Name | Country code |
|---|---|
| South Africa | ZAR |
Abstract
Backgound: Gamma-glutamyl transferase (GGT) has recently been reported as a biomarker for cardiovascular (CVD) risk in general populations. We investigated the associations of GGT with cardio-metabolic diseases and CVD risk in South Africans living with HIV.
Methods: In this cross-sectional study, HIV-infected adults were randomly recruited across 17 HIV clinics in the Western Cape Province. Homeostatic model assessment for insulin resistance (HOMA-IR), hypertension, diabetes, metabolic syndrome by Joint Interim Statement criteria (JIS-MS), a =5% and =10% predicted risk for a CVD event within 10 years by the Framingham risk score (10-years-CVD risk) were computed. Associations between GGT and cardio-metabolic trait were explored using linear and binomial logistic regressions adjusted for age, gender, lifestyle behaviours and HIV-related characteristics.
Results: Among 709 participants (561 women, mean age 38.6 years), log-GGT was positively associated with waist circumference (ß=2.75; p<0.001), diastolic blood pressure (ß=1.65; p=0.006), total cholesterol (ß=0.21; p<0.001), low-density lipoprotein-cholesterol (ß=0.16; p<0.001), high-density lipoprotein-cholesterol and log-triglycerides (both ß=0.12; p<0.001), fasting plasma glucose (ß=0.19; p=0.031), 2-hour-post-glucose-load plasma glucose (ß=0.26; p=0.007), HOMA-IR (ß=0.13; p=0.001), log-high-sensitivity C-reactive-protein (ß=0.3; p<0.001) in linear regression analyses; with hypertension [OR=1.41 (95%CI, 1.13-1.75); p=0.001], JIS-MS [OR=1.33 (1.05-1.68); p=0.016], =5% 10-year-CVD risk [OR=1.55 (1.24-1.9400); p<0.001] and =10% 10-year-CVD risk [OR=1.56 (1.08-2.23); p=0.016] but not with diabetes [OR=1.24 (0.88-1.71), p=0.205] in logistic regression analyses.
Conclusions: In this study, GGT levels were associated with cardio-metabolic variables independent of HIV specific attributes. If confirmed in longitudinal studies, GGT evaluation maybe included in CVD risk monitoring strategies in people living with HIV.
Methods: In this cross-sectional study, HIV-infected adults were randomly recruited across 17 HIV clinics in the Western Cape Province. Homeostatic model assessment for insulin resistance (HOMA-IR), hypertension, diabetes, metabolic syndrome by Joint Interim Statement criteria (JIS-MS), a =5% and =10% predicted risk for a CVD event within 10 years by the Framingham risk score (10-years-CVD risk) were computed. Associations between GGT and cardio-metabolic trait were explored using linear and binomial logistic regressions adjusted for age, gender, lifestyle behaviours and HIV-related characteristics.
Results: Among 709 participants (561 women, mean age 38.6 years), log-GGT was positively associated with waist circumference (ß=2.75; p<0.001), diastolic blood pressure (ß=1.65; p=0.006), total cholesterol (ß=0.21; p<0.001), low-density lipoprotein-cholesterol (ß=0.16; p<0.001), high-density lipoprotein-cholesterol and log-triglycerides (both ß=0.12; p<0.001), fasting plasma glucose (ß=0.19; p=0.031), 2-hour-post-glucose-load plasma glucose (ß=0.26; p=0.007), HOMA-IR (ß=0.13; p=0.001), log-high-sensitivity C-reactive-protein (ß=0.3; p<0.001) in linear regression analyses; with hypertension [OR=1.41 (95%CI, 1.13-1.75); p=0.001], JIS-MS [OR=1.33 (1.05-1.68); p=0.016], =5% 10-year-CVD risk [OR=1.55 (1.24-1.9400); p<0.001] and =10% 10-year-CVD risk [OR=1.56 (1.08-2.23); p=0.016] but not with diabetes [OR=1.24 (0.88-1.71), p=0.205] in logistic regression analyses.
Conclusions: In this study, GGT levels were associated with cardio-metabolic variables independent of HIV specific attributes. If confirmed in longitudinal studies, GGT evaluation maybe included in CVD risk monitoring strategies in people living with HIV.
Producers and sponsors
Primary investigators
| Name | Affiliation |
|---|---|
| Kim A. Nguyen | Non-Communicable Diseases Research Unit, South African Medical Research Council, Cape Town and Durban, South Africa |
| Nasheeta Peer | Non-Communicable Diseases Research Unit, South African Medical Research Council, Cape Town and Durban, South Africa |
| Andre P. Kengne | Non-Communicable Diseases Research Unit, South African Medical Research Council, Cape Town and Durban, South Africa |
Data Collection
Dates of Data Collection
| Start | End |
|---|---|
| 2015-01-01 | 2015-12-31 |